在接受伊洛前列素治疗的系统性硬化症患者中评估心脏纵向应变率的变化:一项观察性研究
研究纳入15例因指端溃疡或指端溃疡史接受伊洛前列素治疗的连续性系统性硬化症患者,在6小时输注前及输注结束时行超声心动图包括整体纵向应变(GLS)检测。伊洛前列素给药后平均GLS显著改善(从-13.5±2.5至-15±3.3,P=0.011),四腔心切面获得的GLS改善更显著(从-13.4±2.2至-15.6±3,P=0.001),GLS改善程度与任何系统性硬化症参数均不相关。作者认为伊洛前列素改善GLS提示心肌灌注增加至少部分纠正了左心室收缩功能障碍,需进一步研究证实并探索中长期效应。
要点
- 15例系统性硬化症患者接受伊洛前列素6小时输注后平均GLS显著改善(从-13.5±2.5至-15±3.3,P=0.011)。
- 四腔心切面GLS分析质量最佳,输注后应变显著改善(从-13.4±2.2至-15.6±3,P=0.001)。
- GLS改善程度与任何系统性硬化症参数均不相关。
核心结论
- 伊洛前列素给药改善了GLS,提示心肌灌注增加至少部分纠正了左心室收缩功能障碍。
- 需要进一步研究证实这些发现,并进一步探索伊洛前列素对心肌收缩的中长期效应。
研究设计与样本
- 观察性研究,纳入15例因指端溃疡存在或病史接受伊洛前列素治疗的连续性系统性硬化症患者(年龄54±11岁;12例女性)。
- 在伊洛前列素给药前及6小时输注结束时行超声心动图检查,包括GLS技术。
主要发现
- 伊洛前列素给药后平均GLS显著改善(从-13.5±2.5至-15±3.3;P=0.011)。
- 四腔心切面获得的超声心动图数据GLS分析质量最佳,伊洛前列素给药后应变显著改善(从-13.4±2.2至-15.6±3;P=0.001)。
- GLS改善程度与任何系统性硬化症参数均不相关。
关键数值与推荐
- 平均GLS在伊洛前列素给药后从-13.5±2.5改善至-15±3.3(P=0.011)。
- 四腔心切面GLS在伊洛前列素给药后从-13.4±2.2改善至-15.6±3(P=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究证实这些发现,并进一步探索伊洛前列素对心肌收缩的中长期效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: SSc is characterized by widespread microangiopathy and fibrosis of skin and visceral organs. Left ventricle involvement is usually subclinical, characterized by systolic and/or diastolic dysfunction. The global longitudinal strain (GLS), a validated and reliable technique for the measurement of ventricular longitudinal deformation by means of echocardiography, may detect subclinical systolic dysfunction of SSc myocardium. The improvement of myocardial perfusion by means of intravenous Iloprost administration could ameliorate the contractility of SSc heart. Therefore, we aimed to evaluate GLS in a series of SSc patients prior and after Iloprost infusion. METHODS: Fifteen consecutive SSc patients (age: 54 ± 11 years; 12 females) treated with Iloprost because of the presence/history of digital ulcers underwent echocardiography, including GLS technique. This evaluation was conducted immediately before Iloprost administration and at the end of the 6-h infusion session. RESULTS: Significant improvement in the mean GLS was observed after Iloprost administration (from -13.5 ± 2.5 to -15 ± 3.3; P = 0.011). The echocardiographic data obtained from the four-chamber view showed the best quality for GLS analysis and showed a highly significant improvement of the strain after Iloprost administration (from -13.4 ± 2.2 to -15.6 ± 3; P = 0.001). The degree of GLS improvement did not correlate with any SSc parameters. CONCLUSION: Iloprost administration improved GLS, suggesting that the increase of myocardial perfusion allowed, at least in part, a correction of left ventricular systolic dysfunction. Further studies are needed to confirm these findings, further exploring the mid/long-term effects of Iloprost on myocardial contraction.
引用
- Isaia I, Aparo P, Castelletti F, et al. Evaluation of changes in cardiac longitudinal strain rate in patients with systemic sclerosis undergoing iloprost treatment: an observational study. Rheumatology (Oxford). 2025. PMID: 39150469. doi:10.1093/rheumatology/keae441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。